Japan Tobacco Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Takehiko Tsutsui
- Full Time Employees
- 52,867
- Sector
- Consumer non-durables
- Industry
- Tobacco
- Address
- 1-1, Toranomon 4-chome Tokyo TY Japan 105-6927
- IPO Date
- Oct 27, 1994
- Website
- jti.co.jp
- Similar Companies
- Business
- Japan Tobacco Inc. Japan Tobacco Inc. (2914.T) is a multinational tobacco company headquartered in Tokyo, Japan, and founded in 1985 through the privatization of the Japan Tobacco and Salt Public Corporation. The company operates primarily in the tobacco segment, manufacturing and marketing cigarettes and other combustibles such as Winston, Camel, MEVIUS, LD, Seven Stars, and Natural American Spirit; reduced-risk products including heated tobacco under Ploom, e-vapor under Logic, nicotine pouches under Nordic Spirit, and infused tobacco under WITH; as well as fine-cut tobacco, snus, pipe tobacco, cigars, and roll-your-own products, with sales in over 130 markets worldwide including significant presence in Japan, Europe, Asia, and the United States. Its processed food business provides frozen and ambient foods like noodles, okonomiyaki, packaged cooked rice; seasonings including yeast extracts; and bakery products, primarily targeting the Japanese market. Geographically, Japan Tobacco maintains approximately 54,000-62,000 employees across 61 factories globally, with Japan Tobacco International headquartered in Geneva, Switzerland, overseeing international operations. In recent developments, the company completed its acquisition of Vector Group Ltd. in October 2024 for approximately USD 2.4 billion, significantly expanding its U.S. market share from 2.3% to about 8.0% and adding top cigarette brands to bolster combustibles profitability and fund reduced-risk product investments. Japan Tobacco announced in May 2025 an agreement to transfer its pharmaceutical business—focused on cardiovascular, renal, metabolism, immunology, and neuroscience drugs, including operations via subsidiary Torii Pharmaceutical—to Shionogi & Co., Ltd. through an absorption-type split effective December 2025 for JPY 5,397 million plus adjustments, enabling full exit from the sector previously established in 1987; this follows ongoing portfolio streamlining, with the business recording JPY 44,942 million in net sales for fiscal 2024.
Company News
Japan Tob (OTCMKTS:JAPAY) Shares Gap Down – Time to Sell?
Japan Tobacco: Strong Earnings Support The Share Price
Japan Tob (JAPAY) Projected to Release Quarterly Earnings on Thursday
JAPAN TOB (JAPAY) Upgraded to Buy: Here's What You Should Know
US FDA proposes rule to tighten oversight of foreign tobacco makers
Japan Tobacco: Steady As She Goes
Japan Tobacco Inc. (JAPAY) Q1 2026 Earnings Call Transcript
Seeking Safety In High Yield Tobacco
Japan Tobacco Inc. (OTCMKTS:JAPAF) Sees Significant Decline in Short Interest
Japan Tobacco Inc. (JAPAY) Q4 2025 Earnings Call Transcript
JAPAN TOB (JAPAY) is a Great Momentum Stock: Should You Buy?
All You Need to Know About JAPAN TOB (JAPAY) Rating Upgrade to Buy
Japan Tob (OTCMKTS:JAPAY) Sets New 1-Year High – Still a Buy?
Contrasting Japan Tob (OTCMKTS:JAPAY) & British American Tobacco (NYSE:BTI)
Japan Tobacco: A 'Buy' On Beat & Raise Quarter, Profitability Outlook
Japan Tobacco Inc. (JAPAY) Q3 2025 Earnings Call Transcript
Japan Tobacco Inc. (JAPAY) Q2 2025 Earnings Call Transcript
High-Yield Tobacco: Relative Quality
Japan Tobacco: Staying Positive On New Product And Non-Core Disposal
Japan Tobacco Inc. (JAPAY) Q1 2025 Earnings Call Transcript